Dexterra Group Inc. (TSE:DXT – Get Rating) – Investment analysts at Atb Cap Markets decreased their FY2022 earnings estimates for shares of Dexterra Group in a report issued on Wednesday, November 9th. Atb Cap Markets analyst C. Murray now forecasts that the company will earn $0.20 per share for the year, down from their prior estimate of $0.31. The consensus estimate for Dexterra Group’s current full-year earnings is $0.59 per share. Atb Cap Markets also issued estimates for Dexterra Group’s Q4 2022 earnings at $0.10 EPS, Q3 2023 earnings at $0.21 EPS, Q4 2023 earnings at $0.18 EPS, Q1 2024 earnings at $0.19 EPS, Q2 2024 earnings at $0.20 EPS and Q3 2024 earnings at $0.25 EPS.
A number of other brokerages also recently weighed in on DXT. National Bankshares cut their price target on shares of Dexterra Group from C$12.00 to C$10.00 in a research report on Wednesday, August 17th. Acumen Capital dropped their target price on shares of Dexterra Group from C$11.50 to C$10.50 in a report on Thursday, August 11th. ATB Capital dropped their target price on shares of Dexterra Group from C$10.00 to C$9.00 in a report on Thursday. Raymond James dropped their target price on shares of Dexterra Group from C$8.00 to C$7.50 and set a “market perform” rating on the stock in a report on Thursday. Finally, Scotiabank dropped their target price on shares of Dexterra Group from C$8.00 to C$7.00 in a report on Thursday.
Dexterra Group Stock Performance
Dexterra Group Company Profile
Dexterra Group Inc provides support services for the creation, management, and operation of infrastructure in Canada. It operates through three segments: Integrated Facilities Management; Modular Solutions; and Workforce Accommodations, Forestry and Energy Services (WAFES). The Integrated Facilities Management segment delivers operation and maintenance solutions for built assets and infrastructure in the public and private sectors, including aviation, defense, retail, healthcare, business and industry, education, rail, hotels and leisure, and government.
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Dexterra Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexterra Group and related companies with MarketBeat.com's FREE daily email newsletter.